Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Artrya Limited ( (AU:AYA) ) just unveiled an announcement.
Artrya Limited has made significant strides in its commercial operations, highlighted by the U.S. launch of its Salix® Coronary Anatomy platform and the submission of its Salix® Coronary Plaque module for FDA clearance. The company secured a five-year contract with Tanner Health, marking its first U.S. commercial revenues, and is preparing for further expansion with strategic partnerships and a clear reimbursement pathway. The leadership transition, with Co-Founder John Konstantopoulos appointed as CEO, aims to drive the company’s transition to a commercially led enterprise, focusing on integrating U.S. and Australian hospital partners and expanding its product utility and revenue base.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$2.21 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is a medical technology company that specializes in the commercialisation of its AI-powered Salix® cloud platform for the assessment and management of coronary artery disease. The company focuses on providing real-time, point-of-care cardiac analysis globally, with a significant market focus in the United States and Australia.
Average Trading Volume: 216,253
Technical Sentiment Signal: Buy
Find detailed analytics on AYA stock on TipRanks’ Stock Analysis page.